Polaris Expands Ludwig Collaboration
The San Diego-based Polaris Group has agreed to expand its collaboration with the Ludwig Institute for Cancer Research on their work together in developing pegylated arginine deiminase (ADI-PEG 20), a promising anti-cancer compound. We recently profiled the company here. Under their expanded collaboration, Polaris and the institute hope to identify other enzymes with potential anti-tumor activity and to further explore ADI-PEG 20 as a cancer therapy. The collaboration builds on the work of Lloyd Old, the Ludwig Institute’s New York branch director and a longtime cancer researcher at the Memorial Sloan-Kettering Cancer Center.